Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Alan Wells
Massachusetts Institute of Technology, Department: Engineering (All Types)
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zyoxel
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
The conflict arises from Investigator's proprietary interest as a co‐inventor of intellectual property licensed to Zyoxel that is being evaluated/developed in bench research funded by a Pitt subaward under Massachusetts Institute of Technology’s prime NIH 5UH2TR000496‐02 All‐Human Microphysical Model of Metastasis Therapy
All-Human Microphysical Model of Metastasis Therapy
Carcinoma morbidity and mortality result overwhelmingly from the dissemination of the tumor beyond the initial site of development, to not only avoid directed surgical and radiological removal but also appear as more resistant to systemic therapies than the primary tumor. Development of new approaches that are obviously needed for these disseminated carcinoma cells is stymied by our dearth of knowledge concerning the tumor biology and how chemotherapy is metabolized in the metastatic niche, particularly in response to cyclic and diurnal rhythms of hormones, nutrients and inflammatory signals. Current in vitro models fail to capture the complexity of the microenvironment, and whole animal models do not allow for real time and continuous monitoring of the events and cell behaviors during the critical first month of establishment. Bioreactors offer a unique window into this period; we propose to develop a next generation all human liver bioreactor that provides physiologic mimicry of the human situation to aid in drug development and therapeutic approaches to metastasized cancers.
Filed on December 12, 2013.
Tell us what you know about Alan Wells's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.